Galderma’ Nemluvio Receives UK’s MHRA & Swissmedic Approval for Atopic Dermatitis and Prurigo Nodularis
Shots:
- The UK’s MHRA & Swissmedic have approved Nemluvio (SC) for mod. to sev. PN & AD, where it is approved in adults for PN & in combination with TCS ± TCI in pts (≥12yrs.; ≥30kg) for AD who are candidates for systemic therapy. Awaits approval in Singapore & Australia
- Approval is based on P-III (OLYMPIA for PN & ARCADIA for AD) trials that showed Nemluvio improved skin lesions, itch, & sleep disturbance in PN & AD pts with favorable safety
- Nemolizumab (mAb) targets IL-31 receptor alpha to inhibit IL-31 signaling, responsible for itch & other symptoms in mod. to sev. AD & PN
Ref: Businesswire | Image: Galderma
Related News:- Galderma’s Nemluvio (Nemolizumab) Secures the EU Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) and Prurigo nodularis (PN)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
